Mankind Pharma Reports Strong Q1 FY27 Results Driven by Revenue Growth and Margins Improvement

Mankind Pharma Reports Strong Q1 FY27 Results Driven by Revenue Growth and Margins Improvement​

New Delhi, India, July 30, 2026: Mankind Pharma Limited, one of India's leading pharmaceutical companies, announced its financial results for the first quarter of Fiscal Year 2027 (Q1 FY27), which ended on June 30, 2026. The company reported a strong performance across key metrics, characterized by solid revenue growth and improved operational efficiency.

The results reflect the consolidated financial statements of the pharmaceutical giant.

Key Financial Highlights for Q1 FY27​

Mankind Pharma saw Revenue from Operations reach INR 4,031 Crore in Q1 FY27, marking a 12.9% increase year over year (YoY). The company's profitability improved significantly, with EBITDA reaching INR 1,060 Crore, representing a 24.7% rise YoY and achieving an EBITDA margin of 26.3%.

The earnings per share reflected this strong performance, with the Diluted EPS standing at INR 13.7, which is up 29.6% YoY. The PAT (Profit After Tax) saw growth, reaching a margin of 14.2%, an improvement of 170 basis points (bps) YoY.

The company’s consolidated financial performance for Q1 FY27 compared to previous periods is detailed below:

Domestic Business Performance Drives Growth​

The domestic business segment (excluding Consumer Healthcare) performed robustly, with revenue growing by 11.0% YoY, reaching INR 3,180 Crore. This growth was propelled by significant double-digit increases in Mankind's core businesses and the specialty segment of BSV.

Key drivers within the therapeutic segments included:

• Chronic Care: The Chronic business grew by 19.4%, while the Cardiac and Anti-diabetes segments saw respective growths of 12.7% and 15.8%.
• Acute & Specialty: Growth was aided by outperformance in Gastro, VMN, and Gynaec businesses. Furthermore, the BSV domestic specialty business recorded strong double-digit growth.
• Brand Strength: Key acute brands like Pantakind (1.8x), Cefakind-CV (1.2x), Nurokind-LC (1.1x), and Dydroboon (1.5x) showed notable outperformance. The Glizid brand family grew 29% YoY, while the Telmikind family saw a 30%/31% growth in Lipirose / Statpure within cardiac care during Q1 FY27.
• BSV Segment: Focused brands such as Foligraf and Humog registered 39% growth, alongside Anti-D at 23%.

Segmental Breakdown Details​

The overall domestic market was segmented into two parts: prescription drugs and consumer healthcare. Prescription drug revenue reached INR 3,180 Crore, contributing to the overall 4,031 Crore total.

Consumer Healthcare business grew by 4% YoY, with revenue at INR 246 Crore. This growth occurred despite a base effect related to discontinued cash and carry businesses. The company reported gaining market share in key brands including Manforce, Preganews, and Gas-o-fast. Additionally, the Mother and E-Com segment share increased to 15% in Q1 FY27, up from 11% in Q1 FY26, supported by a 38% growth.

International Exports Segment Shows Strong Growth​

The Exports business registered healthy growth at an international level. Revenue from the International business grew by 29% YoY, amounting to INR 605 Crore. Mankind (excluding BSV) launched one new product in Q1 FY27, bringing the total number of products launched in the US to 49.

MANKIND Stock Price Movement​

Shares of Mankind Pharma Limited slipped today, settling at ₹2575.9 after registering a 0.88% decline in post-market trading. The equity saw total traded volume of 294,648 shares during the session.